Screening Kidney Transplant Candidates For Coronary Artery Disease

  • Research type

    Research Study

  • Full title

    Canadian-Australasian Randomised Trial of Screening Kidney Transplant Candidates For Coronary Artery Disease (CARSK study)

  • IRAS ID

    281963

  • Contact name

    Debasish Banerjee

  • Contact email

    debasish.banerjee@stgeorges.nhs.uk

  • Sponsor organisation

    University of British Columbia

  • Clinicaltrials.gov Identifier

    NCT03674307

  • Duration of Study in the UK

    5 years, 0 months, 1 days

  • Research summary

    Cardiovascular disease is the most common cause of death for patients with end stage kidney failure while on the kidney transplant waiting list and after transplantation. Current standard care involves screening for coronary artery disease prior to waitlist entry, then at regular intervals, according to perceived risk, until transplanted. This study will help us work out whether regular testing is helpful, by showing us whether there is any difference to what happens to people if they are tested or not.
    The proposed trial will enrol people who are already on the kidney transplant waiting list, and who don’t have any symptoms of new heart problems. Eligible for the study will be any patient active on kidney transplant wait list aged 18y or above. They will be recruited in the 3 participating centres; St George’s Hospital, St Helier Hospital and Royal Sussex County Hospital. The patients enrolled will stay in the study for a maximum of 5 years. While they are in the study, people will be followed up as usual – they will not have to have any extra appointments but will receive a 6-monthly phone call to check wait-list status and exclude any cardiovascular events. They will also be asked to complete cost and quality of life questionnaires. The trial will use chance to allocate people to either getting no regular heart testing while they wait for a kidney transplant, or to get regular heart testing, as per the current standard of care at each centre. We will make sure everyone gets tested if they develop any symptoms of heart problems. The trial will measure what happens to people, and particularly whether they develop any heart problems, whether they get a kidney transplant, and whether they have any heart problems after a transplant.

  • REC name

    London - Dulwich Research Ethics Committee

  • REC reference

    20/LO/1140

  • Date of REC Opinion

    22 Feb 2021

  • REC opinion

    Further Information Favourable Opinion